Publications
Detailed Information
The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Seung-Phil | - |
dc.contributor.author | Shin, Kwang-Soo | - |
dc.contributor.author | Lee, Jeong-Mi | - |
dc.contributor.author | Jung, In-Kyung | - |
dc.contributor.author | Koo, Jimo | - |
dc.contributor.author | Lee, Seung-Woo | - |
dc.contributor.author | Park, Seowoo | - |
dc.contributor.author | Shin, Jieun | - |
dc.contributor.author | Park, Myunghwan | - |
dc.contributor.author | Park, Bongju | - |
dc.contributor.author | Oh, Hanseul | - |
dc.contributor.author | Koo, Bon-Sang | - |
dc.contributor.author | Hong, Jungjoo | - |
dc.contributor.author | Ryu, Choong-Min | - |
dc.contributor.author | Kim, Jae-Ouk | - |
dc.contributor.author | Oh, Taegwon | - |
dc.contributor.author | Kang, Chang-Yuil | - |
dc.date.accessioned | 2022-09-30T05:51:45Z | - |
dc.date.available | 2022-09-30T05:51:45Z | - |
dc.date.created | 2022-06-16 | - |
dc.date.issued | 2022-05 | - |
dc.identifier.citation | Vaccines, Vol.10 No.5, p. 712 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | https://hdl.handle.net/10371/184882 | - |
dc.description.abstract | Several COVID-19 platforms have been licensed across the world thus far, but vaccine platform research that can lead to effective antigen delivery is still ongoing. Here, we constructed AdCLD-CoV19 that could modulate humoral immunity by harboring SARS-CoV-2 antigens onto a chimeric adenovirus 5/35 platform that was effective in cellular immunity. By replacing the S1/S2 furin cleavage sequence of the SARS-CoV-2 Spike (S) protein mounted on AdCLD-CoV19 with the linker sequence, high antigen expression was confirmed in various cell lines. The high levels of antigen expression contributed to antigen-specific antibody activity in mice and non-human primates (NHPs) with a single vaccination of AdCLD-CoV19. Furthermore, the adenovirus-induced T(h)1 immune response was specifically raised for the S protein, and these immune responses protected the NHP against live viruses. While AdCLD-CoV19 maintained neutralizing antibody activity against various SARS-CoV-2 variants, it was reduced to single vaccination for beta and o variants, and the reduced neutralizing antibody activity was restored with booster shots. Hence, AdCLD-CoV19 can prevent SARS-CoV-2 with a single vaccination, and the new vaccine administration strategy that responds to various variants can maintain the efficacy of the vaccine. | - |
dc.language | 영어 | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/vaccines10050712 | - |
dc.citation.journaltitle | Vaccines | - |
dc.identifier.wosid | 000801871200001 | - |
dc.identifier.scopusid | 2-s2.0-85131269813 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | 712 | - |
dc.citation.volume | 10 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kang, Chang-Yuil | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.